EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular Crossroads: Shared and Divergent Molecular Signatures in Alzheimer’s Disease and Dementia with Lewy Bodies

Sandesh Neupane, Tibor Hortobágyi iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262411811 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Sandesh Neupane und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Neuropathology, University Hospital of Zurich, University of Zurich, Schmelzbergstrasse 12, 8091 Zurich, Switzerland. Hauptthemen laut MEDLINE: Alzheimer Disease, Lewy Body Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 182 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) are the two most common forms of dementia due to neurodegeneration. AD is characterized by extracellular amyloid-β (Aβ) plaques and intracellular tau neurofibrillary tangles, whereas DLB is defined by α-synuclein (α-Syn)-containing Lewy bodies. Although AD and DLB exhibit divergent core features, the disorders frequently co-occur and converge on shared endpoints. Co-pathology is common and linked to more severe cognitive decline, faster progression, and clinicopathological heterogeneity. Here, we discuss the current understanding of shared and unique clinical and neuropathological features of AD and DLB. We compare genetic risk and pathological drivers (Aβ and tau in AD; α-Syn in DLB) and their overlapping co-pathology, and review downstream mechanisms—mitochondrial dysfunction, oxidative stress, neuroinflammation, and cerebrovascular contributions, including cerebral amyloid angiopathy. We highlight recent findings from state-of-the-art multi-omics (transcriptomic, proteomic, metabolomic, and single-cell/spatial studies) that reveal convergent and disease-specific molecular signatures of AD and DLB. We outline a framework for emerging next-generation biomarkers—from blood-based and cerebrospinal fluid assays to imaging and digital measures—for diagnosis and stratification, and discuss potential translational implications. Together, these advances help to disentangle shared from disease-specific mechanisms, which is essential for improved diagnosis and the development of precise, disease-modifying therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseLewy Body DiseaseHumansBiomarkersalpha-SynucleinAmyloid beta-Peptidestau ProteinsAnimalsOxidative Stress

Stichwörter der Autor:innen

Alzheimer’s diseasealpha-synucleinamyloid-βbiomarkersdementia with Lewy bodiestau

Substanzen

Biomarkersalpha-SynucleinAmyloid beta-Peptidestau Proteins

Autor:innen und Institutionen

  • Institute of Neuropathology, University Hospital of Zurich, University of Zurich, Schmelzbergstrasse 12, 8091 Zurich, Switzerland.
  • Department of Neurology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.

ORCID-Profile: Tibor Hortobágyi

Zitieren

APA

Neupane, S., & Hortobágyi, T. (2025). Molecular Crossroads: Shared and Divergent Molecular Signatures in Alzheimer’s Disease and Dementia with Lewy Bodies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262411811

Vancouver

Neupane S, Hortobágyi T. Molecular Crossroads: Shared and Divergent Molecular Signatures in Alzheimer’s Disease and Dementia with Lewy Bodies. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262411811

BibTeX
@article{Neupane2025,
  author = {Neupane, Sandesh and Hortobágyi, Tibor},
  title = {Molecular Crossroads: Shared and Divergent Molecular Signatures in Alzheimer’s Disease and Dementia with Lewy Bodies},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262411811}
}
Kostenlos starten →